Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$3.12
▼ $0.02 (-0.6%)
Market data updated: 09/20 01:06 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
$565.90M
Day Range
$3.05 - $3.17
52-Week Range
$2.67 - $6.94
Beta
—
Next Earnings
05.11.2026
Support
$2.72
Resistance
$4.26
PRME is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-39.1% (1Y)
Strengths: 5/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 55.3%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$14.84 vs. price $3.12 (-575.7%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
37
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
7d ago · $3.13
Evidence: Panic-selling score jumped from 4 to 34 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
51
Quality
42
Value
38
Momentum
22
Risk
40
Sentiment
56
Fundamental
30
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Prime Medicine, Inc. has centered on its financial performance and investor interest. The biotech company, focused on developing one-time curative genetic therapies, reported a **Q2 2026 loss of $0.24 per share**, slightly beating analyst expectations but missing revenue targets. Analysts from **BMO Capital and HC Wainwright** have issued **Outperform and Buy ratings**, respectively, with price targets of **$9 and $8**, signaling optimism. The company is also preparing to participate in upcoming investor conferences, including a fireside chat at the **H.C. Wainwright Global Investment Conference**.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Prime Medicine, Inc.. News trend score: 56. Reason: 6 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
51
Psychology
37
Fundamentals
30
Technical
22
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
-3%
Market Narrative
35
Fundamental Reality
51
Narrative Gap
-16
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
PRME’s psychology is fragmented but dominated by **overconfidence** (24), where traders appear to chase momentum over fundamentals—a classic sign of speculative leverage. The **FOMO** signal (23) suggests cautious excitement, but the **narrative gap** (2 points) implies a disconnect between market euphoria and underlying fundamentals. Herding behavior is present but muted, as PRME’s underperformance relative to peers (-3.8% vs. -0.6%) hints at selective participation. The key question: *Will traders double down on momentum or pivot when fundamentals fail to justify the rally?*
Updated: 09/09/2026, 06:43 AM
What could change this?
👥 What the crowd believes
"BMO Capital analyst David Lebowitz initiates coverage on Prime Medicine with an Outperform rating and announces Price Target of $9."
"Prime Medicine reported quarterly losses of $(0.24) per share which missed $1.295M revenue estimate."
🧠 Market Brain events driving this
📈 12D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock divides methodologies sharply, with some seeing resilience and opportunity while others flag severe risks or indifference. Walter Bagehot’s near-perfect score highlights strong liquidity and creditworthiness, suggesting it could weather financial stress, while Charles Mackay and Jesse Livermore’s mid-to-high scores imply a lack of speculative mania and a favorable price trend—aligning with contrarian or trend-following approaches. Conversely, Fisher, Veblen, and Housel’s low scores reflect skepticism: Fisher dismisses it for lacking his signature of quality and growth, Veblen sees it as growth-chasing without substance, and Housel’s zero score warns of volatility that could deter patient investors. Meanwhile, Graham’s dual low scores and Loeb’s warning underscore structural concerns—either the stock fails defensive metrics or carries unacceptable risk, while Marks’ mixed verdict hints at a mid-cycle valuation that may not justify premium pricing.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 99
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 89
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 72
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 69
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 63
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 57
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 33
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 29
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 12
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 8 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-4498.1%
Net Margin
-4342.4%
EBITDA Margin
-4340.0%
ROE
-166.4%
ROA
-58.7%
ROIC
—
EPS
-$1.35
Cash
$63.03M
Total Debt
—
Current Ratio
4.84
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$3.12
Estimated Fair Value (DCF)
-$14.84
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-575.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-158.74M | $-145.63M |
| 2 | -3.1% | $-153.78M | $-129.43M |
| 3 | -1.2% | $-151.86M | $-117.26M |
| 4 | 0.6% | $-152.81M | $-108.25M |
| 5 | 2.5% | $-156.63M | $-101.80M |
Base FCF (last actual year)
$-167.09M
Terminal Value
$-2.47B
Present Value of Terminal Value
$-1.61B
Enterprise Value
$-2.21B
Net Debt
$0
Equity Value
$-2.21B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$0.81
Tangible Book Value per Share (Tangible NAV)
$0.81
Sentiment based on basic keywords (not AI) — 6 positive, 9 neutral, 5 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 17.9.2026
SeekingAlpha · 16.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
Benzinga · 19.8.2026
Benzinga · 19.8.2026
SeekingAlpha · 15.8.2026
SeekingAlpha · 11.8.2026
Benzinga · 10.8.2026
Zacks · 6.8.2026
GlobeNewswire · 6.8.2026
Benzinga · 6.8.2026
Barrons.com · 30.7.2026
Zacks · 30.7.2026
GlobeNewswire · 23.7.2026
Benzinga · 23.7.2026
Insider Monkey · 15.7.2026
Insider Monkey · 15.7.2026
GuruFocus.com · 10.7.2026
Prime Medicine, Inc. (PRME) currently has a StockIQ AI score of 37/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
PRME currently scores 37/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, PRME's estimated fair value is -$14.84, which is 575.7% below the current price of $3.12. This is one valuation model among several signals in the fair-value category, not a price target.
PRME's technical score is 22/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 55.3%; Current ratio: 4.84; Earnings per share (EPS) growth: 18.2%.
Based on the real signals StockIQ computed: Estimated fair value: -$14.84 vs. price $3.12 (-575.7%); Operating margin: -4498.1% (negative); Net margin: -4342.4% (negative).
StockIQ has no recorded dividend payment history for PRME.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Cahill Thomas | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Foster-Cheek Kaye I | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Kelly Michael Aaron | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Marrazzo Jeffrey D | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| NELSEN ROBERT | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Schenkein David P | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Chung Wendy | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| NELSEN ROBERT | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Foster-Cheek Kaye I | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Schenkein David P | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Marrazzo Jeffrey D | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Kelly Michael Aaron | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Cahill Thomas | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Chung Wendy | Grant/Award from Employer | 5.6.2026 | 75,000 | +75,000 | — |
| Makhni Svetlana Ni | Grant/Award from Employer | 16.4.2026 | 800,000 | +800,000 | — |
| Makhni Svetlana Ni | Grant/Award from Employer | 16.4.2026 | 800,000 | +800,000 | — |
| Reine Allan | Grant/Award from Employer | 26.2.2026 | 1,300,000 | +1,300,000 | — |
| Reine Allan | Grant/Award from Employer | 26.2.2026 | 1,300,000 | +1,300,000 | — |
| LEE ANN L. | Grant/Award from Employer | 23.2.2026 | 375,000 | +375,000 | — |
| Alenson Carman | Grant/Award from Employer | 23.2.2026 | 140,000 | +140,000 | — |
| Alenson Carman | Grant/Award from Employer | 23.2.2026 | 140,000 | +140,000 | — |
| LEE ANN L. | Grant/Award from Employer | 23.2.2026 | 375,000 | +375,000 | — |
| Marrazzo Jeffrey D | Grant/Award from Employer | 1.8.2025 | 45,000 | +45,000 | — |
| Marrazzo Jeffrey D | Disposition to the Company | 1.8.2025 | 45,000 | -45,000 | — |
| Marrazzo Jeffrey D | Grant/Award from Employer | 1.8.2025 | 250,000 | +250,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
36,761,940 shares short as of 2026-08-31 · vs. 35,003,578 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
54.1% of trading volume this week was short selling, vs. 48.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology